{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:35:20Z","timestamp":1793838920221,"version":"4.6.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.jacc.2019.02.032","type":"journal-article","created":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T09:44:50Z","timestamp":1552902290000},"page":"2791-2802","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":245,"title":["Effects of Icosapent Ethyl on Total\u00a0Ischemic Events"],"prefix":"10.1016","volume":"73","author":[{"given":"Deepak L.","family":"Bhatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ph. Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliot A.","family":"Brinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven B.","family":"Ketchum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Ralph T.","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Juliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Granowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Tardif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gregson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J.","family":"Pocock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2019.02.032_bib1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jama.295.2.180","article-title":"International prevalence, recognition and treatment of cardiovascular risk factors in outpatients with atherothrombosis","volume":"295","author":"Bhatt","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2019.02.032_bib2","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jama.297.11.1197","article-title":"One-year cardiovascular event rates in outpatients with atherothrombosis","volume":"297","author":"Steg","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2019.02.032_bib3","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/jama.2010.1322","article-title":"Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis","volume":"304","author":"Bhatt","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2019.02.032_bib4","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/CIRCULATIONAHA.114.014796","article-title":"Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the reduction of atherothrombosis for continued health (REACH) registry","volume":"132","author":"Cavender","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.02.032_bib5","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.032_bib6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/eurheartj\/ehu262","article-title":"Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial","volume":"36","author":"Bakal","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.02.032_bib7","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.032_bib8","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","article-title":"Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 Trial","volume":"51","author":"Miller","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.02.032_bib9","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.032_bib10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jacc.2015.10.077","article-title":"Reduction in total cardiovascular events with ezetimibe\/simvastatin post-acute coronary syndrome","volume":"67","author":"Murphy","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.02.032_bib11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jacc.2018.10.039","article-title":"Alirocumab reduces total nonfatal cardiovascular and fatal events in the ODYSSEY OUTCOMES trial","volume":"73","author":"Szarek","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.02.032_bib12","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/eurheartj\/ehu500","article-title":"Triglycerides on the rise: should we swap seats on the seesaw?","volume":"36","author":"Libby","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.02.032_bib13","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jacc.2018.04.061","article-title":"Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management","volume":"72","author":"Ganda","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.02.032_bib14","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C\u2013lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2019.02.032_bib15","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.amjcard.2011.04.015","article-title":"Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial)","volume":"108","author":"Bays","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2019.02.032_bib16","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.amjcard.2012.05.031","article-title":"Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)","volume":"110","author":"Ballantyne","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2019.02.032_bib17","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.02.032_bib18","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1016\/j.bbamem.2016.10.002","article-title":"Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes","volume":"1858","author":"Mason","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jacc.2019.02.032_bib19","first-page":"537","article-title":"A\u00a0randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins","volume":"70","author":"Watanabe","year":"2017","journal-title":"J\u00a0Cardiol"},{"key":"10.1016\/j.jacc.2019.02.032_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.032_bib21","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jacc.2019.01.016","article-title":"Generalizability of the REDUCE-IT trial in patients with stable coronary artery disease. An analysis from the CLARIFY registry","volume":"73","author":"Picard","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.02.032_bib22","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/clc.22692","article-title":"Rationale and design of REDUCE-IT: reduction of cardiovascular events with icosapent ethyl-intervention trial","volume":"40","author":"Bhatt","year":"2017","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacc.2019.02.032_bib23","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.032_bib24","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.032_bib25","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.032_bib26","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.02.032_bib27","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2019.02.032_bib28","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.032_bib29","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa042739","article-title":"Angiotensin-converting-enzyme inhibition in stable coronary artery disease","volume":"351","author":"Braunwald","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.032_bib30","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.032_bib31","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on vardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.032_bib32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.032_bib33","first-page":"1772","article-title":"Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study","volume":"44","author":"Koren","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.02.032_bib34","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.032_bib35","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes, phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2019.02.032_bib36","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.032_bib37","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.032_bib38","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.032_bib39","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.032_bib40","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.032_bib41","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.032_bib42","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.032_bib43","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.032_bib44","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.02.032_bib45","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1161\/CIRCULATIONAHA.112.110536","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations","volume":"126","author":"Rogers","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.02.032_bib46","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/ejhf.29","article-title":"Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved","volume":"16","author":"Rogers","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2019.02.032_bib47","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1161\/CIRCULATIONAHA.117.033065","article-title":"Comparison of time-to-first event and recurrent-event methods in randomized clinical trials","volume":"138","author":"Claggett","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.02.032_bib48","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1080\/01621459.1989.10478873","article-title":"Regression analysis of multivariate incomplete failure time data by modeling marginal distributions","volume":"84","author":"Wei","year":"1989","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.jacc.2019.02.032_bib49","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/(SICI)1097-0258(19970430)16:8<925::AID-SIM545>3.0.CO;2-2","article-title":"Use of the Wei-Lin-Weissfeld method for the analysis of a recurring and a terminating event","volume":"16","author":"Li","year":"1997","journal-title":"Stat Med"},{"key":"10.1016\/j.jacc.2019.02.032_bib50","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1214\/aos\/1176345976","article-title":"Cox\u2019s regression model for counting processes: A large sample study","volume":"10","author":"Andersen","year":"1982","journal-title":"Ann Statist"},{"key":"10.1016\/j.jacc.2019.02.032_bib51","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/1467-9868.00259","article-title":"Semiparametric regression for the mean and rate functions of recurrent events","volume":"62","author":"Lin","year":"2000","journal-title":"J\u00a0R Statist Soc"},{"key":"10.1016\/j.jacc.2019.02.032_bib52","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/biostatistics\/kxl043","article-title":"Joint frailty models for recurring events and death using maximum penalized likelihood estimation: application on cancer events","volume":"8","author":"Rondeau","year":"2007","journal-title":"Biostatistics"},{"key":"10.1016\/j.jacc.2019.02.032_bib53","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1161\/STROKEAHA.118.023384","article-title":"Marine n-3 polyunsaturated fatty acids and the risk of ischemic stroke","volume":"50","author":"Ven\u00f8","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2019.02.032_bib54","doi-asserted-by":"crossref","first-page":"52","DOI":"10.5551\/jat.25593","article-title":"Impact of eicosapentaenoic acid treatment on the fibrous cap thickness in patients with coronary atherosclerotic plaque: an optical coherence tomography study","volume":"22","author":"Yamano","year":"2005","journal-title":"J\u00a0Atheroscler Thromb"},{"key":"10.1016\/j.jacc.2019.02.032_bib55","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.atherosclerosis.2014.02.025","article-title":"Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma","volume":"234","author":"Nishio","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2019.02.032_bib56","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1253\/circj.CJ-15-0813","article-title":"Effects of the addition of eicosapentaenoic acid to strong statin therapy on inflammatory cytokines and coronary plaque components assessed by integrated backscatter intravascular ultrasound","volume":"80","author":"Niki","year":"2016","journal-title":"Circ J"},{"key":"10.1016\/j.jacc.2019.02.032_bib57","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N\u00a0Engl J Med"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719337969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719337969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:21:37Z","timestamp":1760016097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109719337969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":57,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0735109719337969"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2019.02.032","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Icosapent Ethyl on Total\u00a0Ischemic Events","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2019.02.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}